NDAORALTABLET
Approved
Feb 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
TRILAFON (perphenazine) by Merck & Co. is clinical pharmacology pharmacokinetics following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. Approved for schizophrenia, psychotic disorders, bipolar disorder. First approved in 1957.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRILAFON (perphenazine) is a first-generation typical antipsychotic approved in 1957 for schizophrenia, psychotic disorders, and bipolar disorder. It works by antagonizing dopamine receptors in the central nervous system. Perphenazine is extensively hepatically metabolized with a 9-12 hour half-life and shows pharmacokinetic variation based on CYP2D6 metabolizer status.
LOE Approaching
Declining
Legacy product approaching end-of-life with minimal team investment; opportunities limited to maintenance and compliance roles.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics Following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. The plasma elimination half-life of perphenazine was independent of dose and ranged between 9 and 12 hours. In a study in…
Indications (3)
Worked on TRILAFON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.